Supplemental Table 4.
Survival Concordance Probability With SE, Hazard Ratio With 95% CI, and Associated P Value From the LRT for Univariate and Multivariate Analysis Combining Baseline and Day-21 Blood Biomarkers
| Analysis | Marker | Concordance Probability (SE) | Hazard Ratio (95% CI) | LRT P |
|---|---|---|---|---|
| Univariate Analysis Day 21 (NSCLC and SCLC) | CYFRA 21-1a | 0.63 (0.05) | 2.09 (1.41-3.09) | <.001 |
| Ang-2 | 0.57 (0.05) | 0.77 (0.58-1.03) | .090 | |
| FGFba | 0.59 (0.05) | 0.78 (0.60-1.00) | .045 | |
| Final Overall Model (NSCLC Only) | IL-1b ≤ BLQ (baseline) | 0.68 (0.05) | <.001 | |
| IL-1b ≤ BLQ (baseline) + neutrophils (baseline) | 0.75 (0.06) | .029 | ||
| IL-1b ≤ BLQ (baseline) + neutrophils (baseline) + CYFRA 21-1 (day 21)a | 0.78 (0.06) | .004 | ||
| IL-1b ≤ BLQ (baseline) | 3.42 (1.38-8.51) | |||
| Neutrophils (baseline) | 1.08 (1.02-1.14) | |||
| CYFRA 21-1 (day 21)a | 2.07 (1.27-3.38) |
Blood marker thresholds were on the basis of their respective BLQ values. Statistically significant values are shown in bold.
Abbreviations: Ang = angioprotein; BLQ = below limit of quantification; CYFRA 21-1 = cytokeratin-19 antigen; FGFb = basic fibroblast growth factor; IL = interleukin; LRT = likelihood ratio test; NSCLC = non–small-cell lung cancer; SCLC = small-cell lung cancer.
a
Log-transformed.